ANNEXON INC. - COMMON STOCK

Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results

09 May 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in Upcoming May Investor Conferences

05 May 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

07 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference

04 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022

03 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

01 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference

28 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors

20 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment

04 Jan 2022 16:05:01 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

13 Dec 2021 09:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results

09 Nov 2021 16:01:01 By Nasdaq GlobeNewswire

Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer

04 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference

23 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event

20 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update

16 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

22 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Annexon to Present at the Raymond James Human Health Innovation Conference

16 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results

17 May 2021 16:05:01 By Nasdaq GlobeNewswire

Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference

05 May 2021 07:00:01 By Nasdaq GlobeNewswire